New Orleans, LA3 Active Studies

Von Willebrand Disease Clinical Trials in New Orleans, LA

Find 3 actively recruiting von willebrand disease clinical trials in New Orleans, LA. Connect with local research sites and explore new treatment options.

3
Active Trials
2
Sponsors
418
Enrolling

Recruiting Von Willebrand Disease Studies in New Orleans

About Von Willebrand Disease Clinical Trials in New Orleans

Von Willebrand disease is the most common inherited bleeding disorder, caused by deficiency or dysfunction of von Willebrand factor, a protein needed for blood clotting. Most cases are mild with excessive bleeding during surgery or dental work. Treatment includes desmopressin and von Willebrand factor concentrates.

There are currently 3 von willebrand disease clinical trials recruiting participants in New Orleans, LA. These studies are seeking a combined 418 participants. Research is being sponsored by Hemab ApS, University of Washington. Clinical trial participation is free and participants receive study-related medical care at no cost.

Von Willebrand Disease Clinical Trials in New Orleans — FAQ

Are there von willebrand disease clinical trials in New Orleans?

Yes, there are 3 von willebrand disease clinical trials currently recruiting in New Orleans, LA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in New Orleans?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the New Orleans research site will contact you about next steps.

Are clinical trials in New Orleans free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many New Orleans studies also compensate for your time and travel.

What von willebrand disease treatments are being tested?

The 3 active trials in New Orleans are testing new therapies including novel drugs, biologics, and treatment approaches for von willebrand disease.

Data updated October 15, 2026 from ClinicalTrials.gov